A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of S-588410 as adjuvant therapy after curative resection in patients with esophageal cancer

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of S-588410 as adjuvant therapy after curative resection in patients with esophageal cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2015

At a glance

  • Drugs S-288310/S-488310 (Primary)
  • Indications Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors OncoTherapy Science; Shionogi
  • Most Recent Events

    • 27 Mar 2015 Status changed from planning to recruiting as per University Hospital Medical Information Network - Japan .
    • 25 Feb 2015 New trial record
    • 23 Feb 2015 Shionogi will conduct this phase III trial in collaboration with OncoTherapy, according to an OncoTherapy media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top